TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29431549
Drug: Self-paced cycling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-paced cycling (15 min daily for 15 months)
Study: 27803064
Drug: Veliparib (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veliparib (120 mg) with carboplatin and paclitaxel
Study: 24144760
Drug: Alprostadil injection
Normalized name: alprostadil Injection
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alprostadil injection at 10 µg/d for 2 weeks
Study: 24144760
Drug: Sequential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential treatment with alprostadil injection at 10 µg/d for 2 weeks and oral beraprost sodium at 20 µg three times a day for 12 weeks
Study: 24144760
Drug: Strengthened sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strengthened sequential treatment with alprostadil injection at 20 µg/d for 2 weeks and double dose of oral beraprost sodium for 12 weeks
Study: 21563879
Drug: 40 ml
Normalized name: hydrogen peroxide 40 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 ml × 1 blood culture
Study: 21563879
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml × 1 blood culture
Study: 21563879
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml × 2 blood culture
Study: 16476552
Drug: Control cannula
Normalized name: CANNULA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control cannula (CC)
Study: 12620603
Drug: Atropine (muscarinic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (muscarinic blocker)
Study: 10994571
Drug: Drugs specifically
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs specifically prescribed for AD (tacrine, donepezil, and rivastigmine)
Study: 8166473
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy (specific drugs not detailed)
Study: 8166473
Drug: Single agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single agent etoposide
Study: 8166473
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of etoposide and cisplatin
Study: 8166473
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy with hematopoietic growth factors
Study: 2472242
Drug: Tocainide 1800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocainide 1800 mg/day
Study: 2472242
Drug: Tocainide 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocainide 1200 mg + Metoprolol 200 mg
Study: 2472242
Drug: Tocainide 1800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocainide 1800 mg + Metoprolol 200 mg
Study: 28613284
Drug: Activated and
Normalized name: hepatitis A inactivated and hepatitis B (recombinant) vaccine per 1 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated and micronized zeolites (5.4 g once a day for 30 days)
Study: 28613284
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (400 mg D‐alpha tocopheryl acetate once a day for 30 days)
Study: 28613284
Drug: Maltodextrin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maltodextrin (250 mg once a day for 30 days)
Study: 25457497
Drug: Dexamethasone 0.5mg
Normalized name: DEXAMETHASONE 0.5MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 0.5mg once daily
Study: 25457497
Drug: Prednisolone 5mg
Normalized name: PREDNISOLONE 5MG TAB
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone 5mg twice daily
Study: 25457497
Drug: Intermittent dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intermittent dexamethasone 8mg twice daily on days 1-3 every 3 weeks
Study: 23104724
Drug: 10-mg/kg intetumumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-mg/kg intetumumab
Study: 23104724
Drug: 75-mg/m2 docetaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75-mg/m2 docetaxel + 5-mg prednisone + placebo
Study: 21977811
Drug: TCM and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCM and Western medicine
Study: 11087152
Drug: Low/stop corticosteroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low/stop corticosteroid regimen (half dosage for 3 months, then withdrawn)
Study: 11087152
Drug: Control corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control corticosteroid regimen (standard dosage)
Study: 1904310
Drug: CHAP II
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHAP II (hexamethylmelamine dosage‐intensive regimen)
Study: 1904310
Drug: Salvage therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salvage therapy with hexamethylmelamine
Study: 6124495
Drug: i.v. Ranitidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. Ranitidine 50 mg b.d. (or oral ranitidine 150 mg b.d. for up to 10 days)
Study: 21433025
Drug: Pramipexole (0.088
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramipexole (0.088 mg t.i.d. in week 1; 0.18 mg t.i.d. in week 2; 0.7 mg t.i.d. in week 3; 0.18 mg t.i.d. for 3 days and 0.088 mg t.i.d. for the rest of week 4)
Study: 19696778
Drug: Azelnidipine (8-16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelnidipine (8-16 mg day(‐1))
Study: 19696778
Drug: Trichlormethiazide (1-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trichlormethiazide (1-2 mg day(‐1))
Study: 14994318
Drug: Combined extract
Normalized name: POISON IVY/OAK/SUMAC EXTRACTS COMBINED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined extract of Ginkgo biloba (120 mg) and Bacopa monniera (300 mg)
Study: 9817192
Drug: Nitrendipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine (10 mg twice or three times daily)
Study: 27647855
Drug: TGF-b1mAb (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: TGF-b1mAb (2 mg monthly for 12 months)
Study: 27647855
Drug: TGF-b1mAb (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: TGF-b1mAb (10 mg monthly for 12 months)
Study: 27647855
Drug: TGF-b1mAb (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: TGF-b1mAb (50 mg monthly for 12 months)
Study: 23913386
Drug: 80 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg/day telmisartan
Study: 21306709
Drug: Epidural analgesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural analgesia combined with dexamethasone 0.2mg/mL (group II)
Study: 21306709
Drug: Epidural analgesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural analgesia alone using bupivacaine 0.125% and fentanyl 1 μg/mL (group I)
Study: 15577591
Drug: Single intradermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intradermal injection of 99mTc nanocolloidal albumin (Nanocoll)
Study: 11421501
Drug: N-acetylcysteine (NAC),
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC), 600 mg effervescent tablets, once a day for 12 months
Study: 9200056
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group offered screening; specific details on dosage and duration not available.
Study: 9200056
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving usual medical care; specific details on dosage and duration not available.
Study: 19435644
Drug: Normal medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal medical therapy (CPAD-IC)
Study: 17264145
Drug: Salbutamol (Sal;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (Sal; 4 mg)
Study: 14760188
Drug: Enoxaparin and
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin and GP IIb/IIIa inhibitors during PCI
Study: 14760188
Drug: Historical references
Normalized name: typhus, historical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Historical references utilizing unfractionated heparin
Study: 11454883
Drug: Letrozole 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole 0.5 mg daily
Study: 11454883
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate 40 mg qid
Study: 9743505
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol with vaginal micronized progesterone
Study: 9743505
Drug: Estradiol therapy
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol therapy (with and without progesterone)
Study: 7037037
Drug: Etretinate (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etretinate (75 mg daily)
Study: 31650412
Drug: SMART‐3RP intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMART‐3RP intervention (8-session weekly group intervention delivered via videoconferencing)
Study: 30308127
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g of milled flaxseed daily for 1 year
Study: 22592094
Drug: RBV 800
Normalized name: RBV
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: RBV 800 mg/day
Study: 22592094
Drug: RBV 1000/1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBV 1000/1200 mg/day
Study: 14697462
Drug: Atorvastatin 20,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20, 40, and 80 mg/day
Study: 7984617
Drug: Thymogen in
Normalized name: Thyrogen
DrugBank: Thyrotropin alfa (DB00024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thymogen in multi‐modality treatment
Study: 1065802
Drug: Phenylbutazone 300
Normalized name: phenylbutazone 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylbutazone 300 mg/day for 14 days
Study: 1065802
Drug: Indomethacin 210
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin 210 mg/day for 14 days
Study: 1065802
Drug: Pyrasanone 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrasanone 600 mg/day for 14 days
Study: 25910537
Drug: Pegfilgrastim 6
Normalized name: PEGFILGRASTIM 6MG/0.6ML DELIVERY KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegfilgrastim 6 mg on day 7
Study: 25910537
Drug: Daily filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daily filgrastim 5 µg/kg
Study: 25910537
Drug: Pegfilgrastim 6
Normalized name: PEGFILGRASTIM 6MG/0.6ML DELIVERY KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegfilgrastim 6 mg on day 3
Study: 25910537
Drug: Daily filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daily filgrastim
Study: 22495454
Drug: Lung SBRT
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lung SBRT (Stereotactic body radiation therapy)
Study: 17701771
Drug: Low-dose hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-dose hormone replacement therapy (HRT) - estradiol 1 mg/norethisterone acetate 0.5 mg daily
Study: 11174186
Drug: Combined surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined surgical and medical treatment (unilateral endoscopic sinus surgery after pretreatment with oral prednisolone for 10 days and local nasal budesonide bilaterally for 1 month)
Study: 11174186
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment (oral prednisolone and local nasal budesonide)
Study: 3127421
Drug: Both preparations
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both preparations (Humegon and Pergonal)
Study: 21587279
Drug: Polyunsaturated acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyunsaturated acid mixture treatment for 10 weeks
Study: 17716435
Drug: Conventionally treated
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventionally treated nets (using K-O Tab tablets)
Study: 12604518
Drug: Cefpodoxime-proxetil (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefpodoxime-proxetil (100 mg tablet twice daily for 3 days)
Study: 12604518
Drug: Trimethoprim-sulfamethoxazole (double-strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole (double-strength tablet [160/800 mg] twice daily for 3 days)
Study: 11123502
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (91 mg d-alpha-tocopherol)
Study: 11123502
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (250 mg slow-release vitamin C)
Study: 11123502
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Vitamin E and C
Study: 11123502
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Vitamin E and C vs. placebo
Study: 9197299
Drug: ORG 9487
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORG 9487 at 0.75 mg/kg
Study: 9197299
Drug: ORG 9487
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORG 9487 at 1.5 mg/kg
Study: 9197299
Drug: ORG 9487
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORG 9487 at 2 mg/kg
Study: 20447070
Drug: L-T3
Normalized name: L-T3
DrugBank: Liothyronine (DB00279)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-T3
Study: 8913316
Drug: Granulocyte-macrophage colony-stimulating
Normalized name: Granulocyte macrophage-colony stimulating factor
DrugBank: Molgramostim (DB12525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte-macrophage colony-stimulating factor (GM-CSF) administration post-ABMT
Study: 8913316
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no GM-CSF administration)
Study: 1862207
Drug: Desipramine (DMI)
DrugBank: Desipramine (DB01151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desipramine (DMI) 200 mg daily
Study: 6849284
Drug: Diet with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet with 94 g protein
Study: 6849284
Drug: Diet with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet with 65 g protein
Study: 30686560
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of the two strategies (questionnaire and coordination)
Study: 24316553
Drug: GOLFIG regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: GOLFIG regimen (gemcitabine 1000 mg/m² on day 1; oxaliplatin 85 mg/m² on day 2; levofolinate 100 mg/m² on days 1-2; 5-fluorouracil 400 mg/m² bolus followed by 24 h infusion at 800 mg/m² on days 1-2; GM-CSF 100 μg subcutaneously days 3-7; aldesleukin 0.5 MIU bi-daily days 8-14 and 17-30)
Study: 20113691
Drug: Scaling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling and root planing (active treatment)
Study: 12479631
Drug: Hormone/estrogen replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone/estrogen replacement therapy (HRT/ERT)
Study: 2178384
Drug: milrinone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: milrinone (10 mg 4 times a day)
Study: 2178384
Drug: captopril (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: captopril (50 mg 3 times a day)
Study: 26316598
Drug: 24-weekly CD4
Normalized name: Humax-cd4
DrugBank: Zanolimumab (DB17376)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-weekly CD4 testing
Study: 23159435
Drug: Simvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (40 mg twice daily)
Study: 16394035
Drug: HPV16 L1
Normalized name: L1 protein, human papillomavirus type 11 vaccine
DrugBank: Human papillomavirus type 11 L1 capsid protein antigen (DB10300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV16 L1 VLP vaccine
Study: 9744512
Drug: Adjuvant treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant treatments (specific treatments not detailed)
Study: 7640648
Drug: Antagonist passive
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Antagonist passive stretch (APS), 6‐sec maximal voluntary isometric contraction (MVIC) of the antagonist, and subsequent APS
Study: 7640648
Drug: Antagonist passive
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Antagonist passive stretch (APS), 6‐sec MVIC of the antagonist, submaximal concentric contraction of the agonist, and APS
Study: 7640648
Drug: Antagonist passive
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Antagonist passive stretch (APS), submaximal concentric contraction of the agonist, and APS (without MVIC)
Study: 2758730
Drug: Pinacidil 12.5
Normalized name: pinacidil 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pinacidil 12.5 mg with Hydrochlorothiazide 12.5 mg
Study: 2758730
Drug: Pinacidil 37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pinacidil 37.5 mg monotherapy
Study: 2758730
Drug: Pinacidil (0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pinacidil (0, 12.5, 25, and 37.5 mg, b.i.d.)
Study: 2758730
Drug: Hydrochlorothiazide (0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (0, 12.5, and 25 mg, b.i.d.)
Study: 105443
Drug: Orgotein injected
Normalized name: Orgotein
DrugBank: Orgotein (DB11444)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orgotein injected after each daily irradiation session
Study: 15447818
Drug: Glutamine granules
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamine granules (0.5 g.kg(‐1).d(‐1) orally for 7 days)
Study: 15447818
Drug: Placebo (glycine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (glycine, same dosage for 7 days)
Study: 9621674
Drug: Warmed solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warmed solution using HOT LINE
Study: 9621674
Drug: Unwarmed solution
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unwarmed solution
Study: 9621674
Drug: Slow infusion
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow infusion rate
Study: 24062278
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy without CAI
Study: 19492709
Drug: Sealing with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sealing with polyurethane-dimethacrylate foil using a bonding agent
Study: 19492709
Drug: Oral home
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral home care with dental floss and fluoridated toothpaste (Control)
Study: 17227498
Drug: Tadalafil 20
Normalized name: tadalafil 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 20 mg on-demand before sexual activity
Study: 17227498
Drug: Tadalafil 20
Normalized name: tadalafil 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 20 mg three times per week for 5-6 weeks
Study: 9648957
Drug: Omeprazole, 40
Normalized name: Omeprazole, 40 mg oral delayed release capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole, 40 mg b.i.d. for 3 months
Study: 7861594
Drug: Celiac plexus
Normalized name: Bos taurus solar plexus preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celiac plexus block (CPB) with 99.5% ethanol 15-20 ml
Study: 2909549
Drug: Sodium fluoride
Normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium fluoride (25 mg twice daily) with 25-hydroxyvitamin D (50 micrograms twice weekly) and calcium supplements (total calcium intake 1500 mg/day)
Study: 31439531
Drug: Topical antiseptic
Normalized name: BENZALKONIUM CHLORIDE 1.3 mg in 1 mL TOPICAL GEL [Germ Free Topical Antiseptic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical antiseptic ointment
Study: 31439531
Drug: Topical decongestant
Normalized name: Qlearquil Nasal Decongestant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical decongestant ointment
Study: 31439531
Drug: Topical antiseptic
Normalized name: BENZALKONIUM CHLORIDE 1.3 mg in 1 mL TOPICAL GEL [Germ Free Topical Antiseptic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical antiseptic ointment + chemical cauterization
Study: 31439531
Drug: Topical decongestant
Normalized name: Qlearquil Nasal Decongestant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical decongestant ointment + chemical cauterization
Study: 31484191
Drug: Cynara scolymus
Normalized name: Cynara scolymus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cynara scolymus (500 mg twice daily)
Study: 17713973
Drug: CP-481,715 (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP-481,715 (up to 3000 mg)
Study: 17713973
Drug: CP-481,715 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP-481,715 (300 mg) with ciclosporin
Study: 17713973
Drug: CP-481,715 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP-481,715 (300 mg) without ciclosporin
Study: 17713973
Drug: CP-481,715 (escalating
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP-481,715 (escalating doses)
Study: 11162416
Drug: budesonide/formoterol 160/4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: budesonide/formoterol 160/4.5 microg (1 inhalation)
Study: 9783305
Drug: Symptom Score
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptom Score (SS) assessment during treatment for acute lymphoblastic leukemia (ALL)
Study: 9783305
Drug: Symptom Score
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptom Score (SS) assessment during treatment for solid tumors receiving megatherapy with autologous bone marrow rescue
Study: 9783305
Drug: Symptom Score
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptom Score (SS) assessment during treatment for miscellaneous tumors
Study: 2286469
Drug: Fosfomycin trometamol
Normalized name: trometamol
DrugBank: Tromethamine (DB03754)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fosfomycin trometamol (3 g single dose)
Study: 7872756
Drug: Cephalexin (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalexin (0.5 g four times daily for 5 days)